Immune Response Corp. (IMRP)

© quotemedia.com

Today 5d 1m 3m 1y 5y 10y

Last Price 1.25 Tick Change 0.07 Open 1.30 Day High 1.33 Bid 1.23 Ask 1.25 52Wk High 2.10 E.P.S. N/A Ex-Div Date N/A Yield N/A Market Cap N/A

Last Trade 3/9/07 Volume 16.24 k % Change -5.30% Prev Close 1.32 Day Low 1.21 Bid Size 500 Ask Size 500 52Wk Low 0.74 P/E Ratio N/A Dividend N/A Shares N/A Exchange OBB

http://seekingalpha.com/by/symbol/imrp.ob

Immune Response Corporation (IMRP.OB) said that the first patient in a Phase II trial has received NeuroVax, a T-Cell Receptor vaccine for relapsing-remitting multiple sclerosis. NeuroVax is thought to work by enhancing levels of FOXP3+ regulatory T-cells (Treg cells) which reduce the number of pathogenic T-cells in MS patients. Immune Response ended the day at $1.32, a rise of 14 cents.

Biotech stayed in positive territory for the entire session today. The Centient Biotech 200™ closed with a 10-point gain at 3828, a rise of .27%. The S&P moved up .71% and Nasdaq was higher by .55%.